European Primary Care Cardiovascular Society

SGLT2 inhibitor greatly reduced CV risk in HFrEF with or without diabetes

3' education - Sep. 16, 2019 - Paris, France - Prof. John McMurray - Glasgow, UK

Educational information

This video was recorded at the ESC in Paris, France, on September 1, 2019.

Faculty

John McMurray BSc (Hons) MB ChB (Hons) MD FRCP FESC FACC FAHA FRSE FMedSci is Professor of Medical Cardiology and Deputy Director of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow

Disclosures

This recording was independently developed under auspices of EPCCS. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of EPCCS.

Share this page with your colleagues and friends: